CONSTITUENT REPORT
Myrcene
Myrcene is one of the most common acyclic monoterpenes in the AromaForge archive and appears across citrus peel, frankincense, pine, mastic, pink pepper, and many other oil records. Live evidence supports its identity and widespread occurrence, along with a relatively deep preclinical literature touching analgesic, anti-inflammatory, sedative, and safety questions. Human evidence remains limited and the safety picture is mixed, so archive copy should stay chemistry-forward and avoid medical claims.
Chemical identity and composition
PubChem identifies Myrcene as CID 31253 with molecular formula C10H16 and the standard name 7-methyl-3-methylideneocta-1,6-diene. PubChem synonym data confirms that common archive names such as myrcene and beta-myrcene map to the same CAS 123-35-3 entry. In the local archive, myrcene or beta-myrcene is already cited in citrus, frankincense, conifer, parsley herb, and pink-pepper records, reflecting that naming split.
Aroma and practical use
- Use the recorded terpenic, green, balsamic, spicy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2021 review concluded that myrcene has reported anti-inflammatory, analgesic, antioxidant, anxiolytic, and related benefits in many animal studies, while stating that human studies are lacking.
A 2021 review concluded that myrcene has reported anti-inflammatory, analgesic, antioxidant, anxiolytic, and related benefits in many animal studies, while stating that human studies are lacking.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2003 mouse study reported that intraperitoneal myrcene reduced open-field activity, showed motor-relaxant effects at tested higher doses, and prolonged pentobarbital sleeping time, supporting sedative-like central effects in that model.
A 2003 mouse study reported that intraperitoneal myrcene reduced open-field activity, showed motor-relaxant effects at tested higher doses, and prolonged pentobarbital sleeping time, supporting sedative-like central effects in that model.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018 90-day GLP dietary rat study found no myrcene-attributable adverse clinical, pathology, organ-weight, or histopathology findings and set the NOAEL at the highest tested dose.
A 2018 90-day GLP dietary rat study found no myrcene-attributable adverse clinical, pathology, organ-weight, or histopathology findings and set the NOAEL at the highest tested dose.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A 2019 human-cell study reported significant comet-assay DNA damage and chromosomal abnormalities in metabolically competent HepG2/C3A cells at higher tested concentrations of beta-myrcene, highlighting a mechanistic caution signal rather than a real-world exposure conclusion.
A 2019 human-cell study reported significant comet-assay DNA damage and chromosomal abnormalities in metabolically competent HepG2/C3A cells at higher tested concentrations of beta-myrcene, highlighting a mechanistic caution signal rather than a real-world exposure conclusion.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The 2018 subchronic rat study is reassuring for oral exposure in that test system, but it does not resolve all route-specific or long-term human safety questions.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
A 2020 regulatory review states that FDA found no safety concern for flavor use at current use levels, even though older high-dose rodent tumor findings drove delisting under the Delaney Clause.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A 2019 human-cell genotoxicity paper and IARC-related classification history mean the archive should present myrcene safety as mixed rather than unequivocally benign.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
No constituent-specific human clinical safety trial for isolated myrcene was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
CarvacrolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvacrol report →beta-PineneNeutral record
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
traditional · effect
No source citation attached.
Read beta-Pinene report →Terpinen-4-olAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Terpinen-4-ol report →How the effects were investigated
inflammatory pathway modulation
Review literature describes myrcene as interacting with inflammatory signaling and oxidative-stress pathways in preclinical systems, but the mechanism base is not sufficient for therapeutic framing.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
central sedative motor relaxant signal
Mouse work with injected myrcene reported sedative, motor-relaxant, and barbiturate-sleep-potentiating effects, suggesting CNS activity in preclinical models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical efficacy study specific to isolated myrcene was verified in the reviewed public sources.
- Archive naming still splits myrcene and beta-myrcene across oil records, so identity is clear but local normalization remains imperfect.
- A modern constituent-specific fragrance-safety monograph was not separately verified for myrcene in this pass.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.